Candel Therapeutics: pure catalyst, full stop
3 min readPublishes daily2 sourcesAI-written, source-linked. Learn moreNot investment advice. Verify with a financial professional before acting.
58 months of follow-up data, and Candel Therapeutics is still waiting for the only number that matters.
Candel Therapeutics: pure catalyst, full stop
Candel Therapeutics ($CADL) is a catalyst-driven setup built around the expected Q4 2026 BLA submission for aglatimagene besadenovec in newly diagnosed intermediate- to high-risk localized prostate cancer. The bull case is clean on paper: a randomized, placebo-controlled Phase 3 trial run under SPA that hit DFS in the ITT population at HR 0.70 and p=0.0155. A prostate cancer-specific DFS cut tightened that further to HR 0.62 and p=0.0046, and extended follow-up at 58 months pushed it to HR 0.61 and p=0.0031. The bear case is just as simple: the approval argument still rests on recurrence-based endpoints, not survival, and overall survival was similar at the earlier analysis with only 2 prostate cancer deaths total, one in each arm; the downstream endpoints look directionally supportive but not definitive, with time to new anticancer therapy HR 0.72, biochemical failure HR 0.72, and time to metastasis HR 0.58 all carrying confidence intervals that cross 1.0.
Gobble's Take: The scoreboard looks loud. The final whistle still belongs to FDA.
Source: BIOTECH MARKET RESEARCH $CADL | Ep. 1029
Wall Street closed the half with a full-on victory lap
US equity markets finished Tuesday with gains across every major benchmark, and the first half of 2026 ended exactly the way bulls drew it up. The S&P 500 rose 58.93 points to 7,499.36 — a 0.8% move and its best first-half performance since 2020. The Dow Jones Industrial Average added 136.46 points to 52,319.20, setting a fresh all-time high and its strongest first half since 2021. Growth-oriented sectors led the charge, with the Nasdaq Composite surging 1.5% to 26,213.72 and locking in a second-quarter return of approximately 21%. Small-caps refused to sit it out: the Russell 2000 gained 0.5% to 3,024.37, now up 21.9% year-to-date.
Gobble's Take: When every major benchmark is green on the same day, traders stop hunting for excuses and start hunting for the next dip.
Source: PMR Daily Market Round Up - by Public Markets Review
In Case You Missed It
Yesterday's top stories:
Was this briefing useful?
One tap helps Gobbles learn what to cover more carefully.
Get Stock Alerts in your inbox
Free daily briefing. No spam. Unsubscribe anytime.
See something wrong? Report an inaccuracy